165 related articles for article (PubMed ID: 29048389)
1. Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents.
Yao Y; Li R; Liu X; Yang F; Yang Y; Li X; Shi X; Yuan T; Fang L; Du G; Jiao X; Xie P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29048389
[TBL] [Abstract][Full Text] [Related]
2. The vasorelaxant mechanisms of a Rho kinase inhibitor DL0805 in rat thoracic aorta.
Gong L; Peng J; Fang L; Xie P; Si K; Jiao X; Wang L; Du G
Molecules; 2012 May; 17(5):5935-44. PubMed ID: 22609784
[TBL] [Abstract][Full Text] [Related]
3. DL0805-2, a novel indazole derivative, relaxes angiotensin II-induced contractions of rat aortic rings by inhibiting Rho kinase and calcium fluxes.
Yuan TY; Chen YC; Zhang HF; Li L; Jiao XZ; Xie P; Fang LH; Du GH
Acta Pharmacol Sin; 2016 May; 37(5):604-16. PubMed ID: 27041459
[TBL] [Abstract][Full Text] [Related]
4. DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Chen D; Yuan T; Chen Y; Zhang H; Niu Z; Fang L; Du G
Eur J Pharmacol; 2022 Mar; 919():174779. PubMed ID: 35092757
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
7. Vasodilatory effect of a novel Rho-kinase inhibitor, DL0805-2, on the rat mesenteric artery and its potential mechanisms.
Yuan TY; Yan Y; Wu YJ; Xu XN; Li L; Jiao XZ; Xie P; Fang LH; Du GH
Cardiovasc Drugs Ther; 2014 Oct; 28(5):415-24. PubMed ID: 25086815
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.
Hou S; Yang X; Yang Y; Tong Y; Chen Q; Wan B; Wei R; Lu T; Chen Y; Hu Q
Eur J Med Chem; 2021 Aug; 220():113482. PubMed ID: 33906048
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 1
Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
Wang L; Qi J; Fan M; Yao L
Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
[TBL] [Abstract][Full Text] [Related]
13. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
15. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.
Abbhi V; Saini L; Mishra S; Sethi G; Kumar AP; Piplani P
Bioorg Med Chem; 2017 Nov; 25(21):6071-6085. PubMed ID: 29033348
[TBL] [Abstract][Full Text] [Related]
17. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
18. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
20. N
Aboelfotouh HG; Abdallah M; Khalifa H; Aboushady Y; Abadi AH; Engel M; Abdel-Halim M
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2400020. PubMed ID: 38478964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
